Arovella Newsletter May 2023
Hello and welcome to our quarterly update on the activities of your company. It’s been a productive quarter and in this edition we’re focussing on the business side of the ledger as well as our science progression.
Highlights:
Strengthened leadership team with appointment of new Board Chair and key members of management team;
Exciting new data generated for ALA-101 and accepted for presentation at AACR Annual Meeting;
Promising in vitro data for ALA-101 in combination with Imugene’s CF33 oncolytic virus with program progressing to in vivo testing;
Oversubscribed placement to raise $1.6 million; and
Strong investor engagement via Explanatory Webinar.
Dr. Michael Baker
CEO and MD
